Notes from Dr. Burzynski:

1. Cancer is the disease of information processing which I described in the article in 1986.

2. This “computer software“ consists of the network of mutated genes - and in most
   patients these genes are not inherited as mutated. The mutations occur during a
  patient’s life. The “software” instructs the body to make billions of malignant cells.

3. This “software” should be removed from patient’s body. As long as it stays in the
   body the cancer will come back.

4. This is the reason why standard of care can’t cure advanced cancer with surgery,
   radiation and chemotherapy, while they decrease tumor size they can’t remove the mutated genes.

5. Antineoplastons have a chance to do it because based on laboratory studies they
   affect 112 important genes. Clinical data confirms this activity. Mutated genes are
   gone from the blood of responding patients within several months of treatment.

6. The response can be augmented by adding prescription gene targeted medications
  which work on genes not covered by Antineoplastons. However, currently, the
  available medications work only on single or several genes. When they are administered
  without Antineoplastons they are unable to remove all mutated genes. It should be
  noted that in cancer there are from 40 to 650 mutated genes, the highest number in
  Glioblastoma brain cancer.

7. Texas Right to Try permitted the use of Antineoplastons in terminal cancer patients.

8. Combination of Antineoplastons with targeted medications permitted
  obtain remarkable responses in patients who were not supposed to respond to any
  treatment. In 66% to over 80% of terminal patients diagnosed with 38 different
  types of cancer the tumors were gone or markedly decreased and in many patients
  mutated genes were gone from the blood via advanced blood testing.

  It should be stressed that these are the results coming from private practice at
  Burzynski Clinic and not from clinical trials. Terminal cancer patients are usually
  not admitted to clinical trials.

9. Antineoplastons turn off the activity of oncogenes which cause cancer and turn on
  tumor suppressor genes which fight cancer. It translates to the elimination of signals
  generated by these mutated genes. These signals (or pieces of information) are
  necessary for cancer cells’ survival and the lack of them causes cancer cell deaths.

10. I introduced the name of “cyber war” on cancer for this approach to cancer
   treatment.

11. The research by other scientists helped to introduce very sensitive genomic tests
   which are covered by insurance. The results of these tests are available within one
   to four weeks.

12. Identification of mutated genes helps to design the best treatment plan and follow-up
    to the patient’s response based on repeated genomic blood tests.